Debiopharm Competitors and Similar CompaniesClear all

Debiopharm's competitors and similar companies include Sunshine Biopharma, Turning Point Therapeutics and Pyxis Oncology.

	Debiopharm Debiopharm is a biopharmaceutical company specializing in oncology and bacterial infections.	Sunshine Biopharma Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.	Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.	Pyxis Oncology Pyxis Oncology is a preclinical oncology company focused on developing therapeutics to target difficult-to-treat cancers.
Founding Date	Founding Date 1979	Founding Date 2006	Founding Date 2013	Founding Date 2019
Type	Type Private	Type Public	Type Subsidiary	Type Public
Tags	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma
Locations	Locations Lausanne, CH HQ Oss, NL	Locations Pointe-Claire, CA HQ	Locations San Diego, US HQ	Locations Cambridge, US HQ
Employees	Employees 4771% decrease	Employees 5218% increase	Employees 474% decrease	Employees 39
Valuation ($)	Valuation ($) N/A	Valuation ($) 5.8 m	Valuation ($) N/A	Valuation ($) 227 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $36.3m (FY, 2025)	Revenue (est.) $30.8m (FY, 2021)	Revenue (est.) $13.9m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $24.1m (FY, 2025)	Cost of goods N/A	Cost of goods $2.4m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $12.3m (FY, 2025)	Gross profit N/A	Gross profit $11.5m (FY, 2025)
Net income	Net income N/A	Net income ($6m) (FY, 2025)	Net income ($236.6m) (FY, 2021)	Net income ($79.6m) (FY, 2025)
Funding
Total funding raised	Total funding raised $ 2.1m	Total funding raised N/A	Total funding raised $ 144.4m	Total funding raised $ 174m